LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Kodu・Aktsiate loetelu・Galectin Therapeutics Inc

Galectin Therapeutics Inc

Suletud

SektorTervishoid

5.69 3.64

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.06

Max

5.88

Põhinäitajad
By Trading Economics
Sissetulek	-663K -8.2M
Kasumimarginaal	-33,241.667
Töötajad	15
EBITDA	-671K -6.4M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+9.29% upside

Turustatistika
By TradingEconomics
Turukapital	53M 388M
Eelmine avamishind	2.05
Eelmine sulgemishind	5.69

Uudiste sentiment

By Acuity

50%

195 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

1.19 / 1.33 Toetus ja vastupanu

Galectin Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2025, 22:02 UTC

Tulu

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10. dets 2025, 21:46 UTC

Tulu

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10. dets 2025, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10. dets 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10. dets 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10. dets 2025, 23:20 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10. dets 2025, 23:15 UTC

Tulu

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10. dets 2025, 22:59 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10. dets 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10. dets 2025, 22:40 UTC

Tulu

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. dets 2025, 22:06 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. dets 2025, 22:02 UTC

Tulu

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. dets 2025, 22:00 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10. dets 2025, 21:53 UTC

Tulu

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. dets 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10. dets 2025, 21:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

10. dets 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10. dets 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. dets 2025, 21:33 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10. dets 2025, 21:32 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10. dets 2025, 21:25 UTC

Tulu

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. dets 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10. dets 2025, 21:16 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10. dets 2025, 21:15 UTC

Tulu

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10. dets 2025, 21:14 UTC

Tulu

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10. dets 2025, 21:14 UTC

Tulu

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Võrdlus sarnastega

Hinnamuutus

Galectin Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

9.29% tõus

12 kuu keskmine prognoos

Keskmine 6 USD 9.29%

Kõrge 6 USD

Madal 6 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Galectin Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Galectin Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.19 / 1.33Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

195 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.